Browsing by Author "Göksel T."
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Drug allergy in tertiary care in Turkey: Results of a national survey. The ADAPT study: Adult drug allergy perception in Turkey(Elsevier Doyma, 2014) Çelik G.E.; Karakaya G.; Öztürk A.B.; Gelincik A.; Abadoğlu T.; Sin A.; Damadoğlu E.; Yilmaz T.I.; Demirtürk M.; Dursun B.; Özdemir S.K.; Çelikel S.; Değirmenci P.; Bozkurt B.; Göksel T.; Erkekol F.; Aydin T.; Kavut A.B.; Kirmaz C.; Kalpaklioğlu F.; Büyüköztürk S.; Kalyoncu F.Background: No data are available on the incidence of drug hypersensitivity (DH) reactions in outpatient settings of tertiary allergy/immunology clinics. Our aims were to document the frequency of outpatient hospital admissions due to DH reactions to allergy/immunology clinics in adults and the management of these reactions in real life. We also investigated whether drug allergy affected social and medical behaviours of the patients. Methods: This multi-centre study was performed for one year with the participation of 11 out of 16 tertiary allergy/clinical immunology clinics in Turkey. The study group consisted of the patients with DH reactions. Results of a questionnaire including drug reactions and management were recorded. Results: Among 54,863 patients, 1000 patients with DH were enrolled with a median of 2.1% of all admissions. In real life conditions, the majority of approaches were performed for finding safe alternatives (65.5%; 1102 out of 1683) with 11.7% positivity. Diagnostic procedures were positive in 27% (154/581) of the patients. The majority of the patients had higher VAS scores for anxiety. A total of 250 subjects (25%) reported that they delayed some medical procedures because of DH. Conclusion: Our results documented the frequency of admissions due to DH reactions to allergy/clinical immunology clinics for the first time. Although physicians mostly preferred to perform drug tests in order to find safe alternatives, considering the fact that DH was confirmed in 27% of the patients, use of diagnostic tests should be encouraged, if no contraindication exists in order to avoid mislabelling patients as DH. © 2013 SEICAP.Item Patient and physician delay in the diagnosis and treatment of non-small cell lung cancer in Turkey(Elsevier Ltd, 2015) Yurdakul A.S.; Kocatürk C.; Bayiz H.; Gürsoy S.; Bircan A.; Özcan A.; Akkoçlu A.; Uluorman F.; Çelik P.; Köksal D.; Ulubaş B.; Sercan E.; Özbudak T.; Göksel T.; Önalan T.; Yamansavci E.; Türk F.; Yuncu G.; Çopuraslan T.; Mardal T.; Tuncay E.; Karamustafaoğlu A.; Yildiz P.; Seçik F.; Kaplan M.; Çağlar E.; Ortaköylü M.; Önal M.; Turna A.; Hekimoğlu E.; Dalar L.; Altin S.; Gülhan M.; Akpinar E.; Savas T.; Firat N.; Çamsari G.; Özkan G.; Çetinkaya E.; Kamiloğlu E.; Çelik B.; havlucu Y.Aim: The early diagnosis and treatment of lung cancer are important for the prognosis of patients with lung cancer. This study was undertaken to investigate patient and doctor delays in the diagnosis and treatment of NSCLC and the factors affecting these delays. Materials and methods: A total of 1016 patients, including 926 (91.1%) males and 90 (8.9%) females with a mean age of 61.5. ±. 10.1 years, were enrolled prospectively in this study between May 2010 and May 2011 from 17 sites in various Turkish provinces. Results: The patient delay was found to be 49.9. ±. 96.9 days, doctor delay was found to be 87.7. ±. 99.6 days, and total delay was found to be 131.3. ±. 135.2 days. The referral delay was found to be 61.6. ±. 127.2 days, diagnostic delay was found to be 20.4. ±. 44.5 days, and treatment delay was found to be 24.4. ±. 54.9 days. When the major factors responsible for these delays were examined, patient delay was found to be more frequent in workers, while referral delay was found to be more frequent in patients living in villages (. p<. 0.05). We determined that referral delay, doctor delay, and total delay increased as the number of doctors who were consulted by patients increased (. p<. 0.05). Additionally, we determined that diagnostic and treatment delays were more frequent at the early tumour stages in NSCLC patients (. p<. 0.05). Discussion: The extended length of patient delay underscores the necessity of educating people about lung cancer. To decrease doctor delay, education is a crucial first step. Additionally, to further reduce the diagnostic and treatment delays of chest specialists, multidisciplinary management and algorithms must be used regularly. © 2015 Elsevier Ltd.Item Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer(SpringerOpen, 2016) Eser S.; Göksel T.; Erbaycu A.E.; Baydur H.; Başarık B.; Yanık A.Ö.; Gürsul K.K.; Çelik P.; Ediz E.Ç.; Hatipoğlu O.; Yayla B.A.; Başer S.; Eser E.Background: Our purpose is to examine the relationship of Health related quality of life measured by EORTC QLQc30, QLQ-LC13; FACT-L, LCSS, Eq5D) with survival in advanced lung cancer patients. A total of 299 Lung Cancer (LC) patients were, included in this national multicenter Project entitled of “the LC Quality of Life Project (AKAYAK). Baseline scores were analyzed by using Cox’s proportional hazard regression to identify factors that influenced survival. Univariate and multivariate models were run for each of the scales included in the study. Results: Mean and median survival were 12.5 and 8.0 months respectively. Clinical stage (as TNM), comorbidity; symptom scales of fatigue, insomnia, appetit loss and constipation were associated with survival after adjustment for age and sex. Global, physical and role functioning scales of QLQc30; physical and functional scales of LCS and TOI of the FACT-L was also associated with survival. Mobility and Usual activities dimensions of the Eq5D; Physical functioning and the constipation symptom scale of the QLQ-c30; and LCS and TOI scores of the FACT-L remained statistically significant after adjustment. LC13 and LCSS scales were not predictors of survival. Conclusions: HRQOL serves as an additional predictive factor for survival that supplements traditional clinical factors. Besides the strong predictive ability of ECOG on survival, FACT-L and the Eq5D are the most promising HRQOL instruments for this purpose. © 2016, The Author(s).Item COVID-19 pandemic and the global perspective of turkish thoracic society(AVES, 2020) Köktürk N.; İtil B.O.; Altınışık G.; Adıgüzel N.; Akgün M.; Akyıldız L.; Altın S.; Arıkan H.; Ateş G.; Ay P.; Aykaç N.; Babayiğit C.; Bostan P.; Cinel G.; Çalışır H.C.; Çelik P.; Çetinkaya P.D.; Dağlı E.; Demir A.U.; Demir C.; Dikensoy Ö.; Edis E.Ç.; Elbek O.; Erdinç M.; Ergan B.; Eyüboğlu A.F.Ö.; Gemicioğlu B.; Göksel T.; Gülhan E.; Gültekin Ö.; Gürkan C.G.; Gürgün A.; Havlucu Y.; Başoğlu O.K.; Karakurt S.; Karakurt Z.; Kılınç O.; Kocabaş A.; Kul S.; Müsellim B.; Naycı S.; Özkan M.; Pınarer Ö.; Saltürk C.; Sandal A.; Sayıner A.; Şen E.; Şimşek G.Ö.; Karadağ B.T.; Akyıl F.T.; Töreyin Z.N.; Uçan E.S.; Küçük F.Ç.U.; Varol A.; Yasin Y.; Yıldız T.; Arzu Yorgancıoğlu A.; Bayram H.It has been more than 3 months now since the first case of COVID-19 was reported in Turkey. Globally, the number of confirmed cases and deaths reached 9,653,048 and 491,128 respectively, as reported by 216 countries by June 27, 2020. Turkey had 1,396 new cases, 194,511 total cases, and 5,065 deaths by the same date. From the first case until today, the Turkish Thoracic Society (TTS) has been very proactive in educating doctors, increasing public awareness, undertaking academic studies, and assisting with public health policies. In the present report, social, academic, and management perspectives of the pandemic are presented under appropriate subtitles. During this critical public health crisis, TTS has once again demonstrated its readiness and constructive stance by supporting public health, healthcare workers, and the environment. This review summarizes the perspective of TTS on each aspect of the COVID-19 pandemic and casts light on its contributions. © 2020 by Turkish Thoracic Society.